UnknownNot applicableNCT05492643

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhongnan Hospital
Principal Investigator
Xinghuan Wang
Wuhan University
Intervention
one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)(biological)
Enrollment
1000 target
Eligibility
18 years · All sexes
Timeline
2022 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05492643 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome →

← Back to all trials